cadonilimab
cadonilimab drug profile: sponsors, targets, indications, therapeutic areas and regulatory status with source links.
MODALITYPD-1/CTLA-4 bispecific antibody
TARGETSPD-1 · CTLA-4
ALIASESAK104 · Kaitanni
Indications
Therapeutic areas
Regulatory status
NMPAApproved in China
Sponsors and developers
Primary and company sources
Status labels summarize public records and do not replace regulator databases or prescribing information.
Evidence & limits
Source: Open the source record
- Record identifier
- /drugs/cadonilimab/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.